Antidepressant Therapy for Bipolar II Major Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00641927
Recruitment Status : Completed
First Posted : March 24, 2008
Last Update Posted : March 24, 2008
Information provided by:
Stanley Medical Research Institute

Brief Summary:
This study examines the relative safety and benefit of antidepressant therapy (versus recommended mood stabilizer therapy)of bipolar type II major depressive episode. We hypothesize that antidepressant therapy will be superior to mood stabilizer therapy with little or no difference in treatment emergent manic symptoms.

Condition or disease Intervention/treatment Phase
Bipolar Type II Disorder Drug: Venlafaxine Drug: Lithium Carbonate Phase 4

Detailed Description:
Bipolar type II (BP II) major depressive episode (MDE), affects 2.5% of the US adult population and results in an estimated healthcare cost of $40 billion annually. BP II disorder is a distinct clinical entity that differs from BP I disorder, and is characterized by a preponderance of MDEs that result in particularly high morbidity and mortality rates. The treatment of BP II MDE remains a challenge for clinicians. Concerns over antidepressant drug (AD) induced manic switch episodes have led current practice guidelines to recommend treating BP II MDE with mood stabilizer (MS) monotherapy and to avoid AD monotherapy. To date, there are no controlled clinical trials to test the validity of these empirical guidelines. Results from our preliminary BP II MDE studies have shown that fluoxetine monotherapy may be safe and effective initial treatment of BP II MDE with a low manic switch rate. Based upon these observations, we now ask (Specific aim #1): "What is the relative safety and efficacy of initial AD monotherapy vs. MS monotherapy of BP II MDE?" and "What is the relative manic switch rate of initial AD vs. MS monotherapy of BP II MDE?" To answer these questions, patients with BP II MDE will be treated in a 12-week, randomized, parallel group comparison of venlafaxine monotherapy vs. lithium monotherapy. We hypothesize that AD monotherapy will have superior efficacy vs. MS monotherapy, and that there will be a similar manic switch rate among both treatment conditions. If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Acute Antidepressant Therapy in Bipolar II Major Depression
Study Start Date : April 2002
Primary Completion Date : October 2006
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Drug: Venlafaxine
37.5 mg - 375 mg daily, 12 Weeks
Other Name: Effexor-XR
Active Comparator: 2
Drug: Lithium Carbonate
300 mg - 2100 mg daily, 12 weeks
Other Name: Lithium

Primary Outcome Measures :
  1. Reduction in Hamilton Depression Rating Scale score. [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Change in Young Mania Rating Scale score. [ Time Frame: 12 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • men and women (all races and ethnicity) greater than or equal to18 years of age,
  • DSM IV diagnosis of BP II disorder,
  • Current DSM IV MDE,
  • HAM-D17 score greater than or equal to 16,
  • Drug free from prior psychotropic medication greater than or equal to 7 days (2 weeks for MAOIs)

Exclusion Criteria:

  • History of mania,
  • Other primary DSM IV Axis I diagnosis,
  • Alcohol or drug dependence within 3 months,
  • History of nonresponse to Effexor-XR or lithium in the present MDE,
  • History of allergic reaction to Effexor-XR or lithium,
  • Medical contraindications to treatment with Effexor-XR or lithium,
  • Unstable medical condition,
  • Pregnant or breast-feeding women,
  • Women of child-bearing potential not using a medically approved form of contraception,
  • Actively suicidal or requiring hospitalization,
  • Requiring concurrent antidepressant, neuroleptic or mood stabilizer therapy,
  • Prior investigational study within 4 weeks of starting active therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00641927

United States, Pennsylvania
Depression Research Unit, Department of Psychiatry, University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104-3309
Sponsors and Collaborators
Stanley Medical Research Institute
Principal Investigator: Jay D Amsterdam, MD Depression Research Unit, School of Psychiatry, University of Pennsylvania

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jay D. Amsterdam, MD, University of Pennsylvania Identifier: NCT00641927     History of Changes
Other Study ID Numbers: 01-005
First Posted: March 24, 2008    Key Record Dates
Last Update Posted: March 24, 2008
Last Verified: March 2008

Keywords provided by Stanley Medical Research Institute:
bipolar disorder
bipolar type II disorder
mood stabilizer
lithium carbonate

Additional relevant MeSH terms:
Depressive Disorder, Major
Behavioral Symptoms
Depressive Disorder
Mood Disorders
Mental Disorders
Antidepressive Agents
Lithium Carbonate
Venlafaxine Hydrochloride
Psychotropic Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Neurotransmitter Agents
Antidepressive Agents, Second-Generation